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In the global information age, with
more and more tools available to dissem-
inate health information, medical journals
still occupy a unique position of influence
as trusted sources of information—clearly
different from the vast majority of medical
information produced and disseminated
daily.
But along with this influence comes a
unique set of responsibilities. Medical
journals are expected to be impartial
arbiters of the research submitted to them.
However, the pressures on journals to
publish papers have increased year after
year as the rewards to authors, their
institutions, and the funders of the work
for publication increase. Aware of such
external pressures, journals now rightly
expect authors to consider and declare all
potential sources of conflict [1]. Perhaps
less well understood, or at least discussed,
is that journals themselves also experience
pressure—to be profitable, or at least self-
sustaining in order to survive; and to
maintain and even enhance the journal’s
reputation within communities of authors,
readers, and other journals.
In a paper published this week in PLoS
Medicine the potential influence of some of
these pressures on journals are examined.
Andreas Lundh and colleagues [2] exam-
ined clinical trial reports in six general
medical journals over two time periods.
(Note: this analysis does not include PLoS
Medicine as it did not launch until after the
first time period.) The authors asked
whether there could be any association of
the publication of these papers with the
journals’ finances or their calculated
impact factor (not exactly the same as
the impact factor released by Thomson
ISI) and whether that association changed
over time. The conclusion that publication
of industry-supported trials is associated
with a disproportionate increase in cita-
tions, and that sales of reprints from these
papers are a substantial source of income
for journals, is perhaps not surprising, but
it is alarming.
There are, of course, caveats in this
analysis—for example, the increased num-
ber of citations for industry-funded clinical
trials may indicate that these papers were
especially important trials. Nonetheless,
the paper will not be comfortable reading
for any editor of a biomedical journal.
Even though there is no suggestion in this
paper that any editorial decisions were
made with an eye on reprint sales or
citations, the analysis does show that the
potential income, and the disproportionate
number of citations from papers with a
clear commercial interest, present a po-
tential source of conflict for journals aside
from any conflicts for authors or funders of
these studies.
Much has been written about problems
with reprint sales and impact factors [3–6].
This paper, by showing an association of
industry-funded trials with citations and
reprint sales, provides further evidence
that these two pressures—unless handled
carefully and transparently by journals—
may lead to questions about whether such
potential competing interests are accept-
able. It should thus serve as a wake-up call
for every journal that makes a substantial
living from reprints to examine how they
manage such potentials for conflict.
What are the defenses journals can use
against these competing interests? The first
is to promote a wide awareness of all the
potential competing interests that can arise
during publication, not just those of
authors. Journals have been keen to
publish on the potential misdemeanors of
authors, but have been less interested in
those of journals and publishers. Papers
such as Lundh and colleagues’ thus serve
an important function in bringing such
topics to debate. The second defense is for
journals themselves to be transparent in
their handling of their own potential
financial and nonfinancial biases, which
could stem from ownership relationships,
publication models, and relationships with
partner organizations, among others.
There are already a number of editorial
organizations that promote best practices
in scholarly publishing [1,7,8]. Though
mostly they deal with concerns about
authors and reviewers, there is some
guidance for editors on their own conflicts
[9], though rarely about the journals’
conflicts.
In the summary of their paper, Lundh
and colleagues make a further, more
radical suggestion—that medical journals
publish their annual returns. We agree
that this is appropriate. PLoS discloses its
finances in a number of ways: In the 990
report we are required to publish as a
nonprofit organization registered in the
US and in our progress report [10]. In the
interest of further transparency PLoS
Medicine’s sources of income for 2009 are
listed in the footnote to this article and we
intend to place them each year on the
page that currently lists the editors’
competing interests [11]. Similarly, we’d
argue that journals should consider wheth-
er the chasing of impact factors may also
be a source of bias that needs to be
recognized and declared. For us, we wish
to make our relationship with the impact
factor clear: Although the PLoS journals
are all indexed by ISI and hence an
impact factor is calculated for each, PLoS
does not promote impact factors anywhere
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authors and readers to assess the impact of
individual articles via the article-level
metrics we provide with each article [12].
The internet has spurred an intellectual
revolution in the dissemination of medical
information. Journals have thus far been
accepted as one of the most trusted sources
of information. It’s clear, however, that in
order to maintain that trust, journals and
editors need to continue to consider all the
pressures that can arise in publishing and
put in place robust, transparent proce-
dures for handling all the potential con-
flicts that can arise, whether they are those
of authors, editors, or the journals them-
selves.
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